AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A pharmaceutical composition comprising the following ingredients (A) and (B):

Ingredient (A): An alkyl ether derivative represented by the following formula:

$$R^{1}$$
— CH - $(CH_{2})_{m}$ - O — $(CH_{2})_{\overline{n}}$ - N
 R^{4}

which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R² represents a hydrogen atom or a hydroxyl group; R³ and R⁴, which may be the same or different, each represents a substituted or unsubstituted an alkyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a substituted or unsubstituted eyelic amino group an azetidine ring; m represents an integer of 1 to 5; and n represents an integer of 1 to 6 2 to 3; or a salt thereof,

Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

2. - 3. (Canceled)

4. (Currently Amended) A method of preparing a medicament comprising combining the following ingredients (A) and (B),

Ingredient (A): An alkyl ether derivative represented by the following formula:

$$R^{1}$$
— CH - $(CH_{2})_{m}$ - O — $(CH_{2})_{\overline{n}}$ - N
 R^{4}
 R^{4}

which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R² represents a hydrogen atom or a hydroxyl group; R³ and R⁴, which may be the same or different, each represents a substituted or unsubstituted an alkyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a substituted or unsubstituted eyelic amino group an azetidine ring; m represents an integer of 1 to 5; and n represents an integer of 1 to 6 2 to 3; or a salt thereof,

Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

$$5. - 6.$$
 (Canceled)

7. (Currently Amended) A pharmaceutical composition as claimed in claim 1 wherein the pharmaceutical composition is administered to a patient to improve cerebral function treat Alzheimer's disease.

- 8. (Currently Amended) A method as claimed in claim 4 further comprising administering the medicament to a patient in order to improve cerebral function treat Alzheimer's disease.
- 9. (New) The pharmaceutical composition as claimed in claim 1, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·or a salt thereof.
- 10. (New) The pharmaceutical composition as claimed in claim 1, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·maleate.
- 11. (New) The method as claimed in claim 4, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·or a salt thereof.
- 12. (New) The method as claimed in claim 4, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·maleate.